RxDx assay as a companion diagnostic to identify c-Met protein expression in non-squamous NSCLC patients eligible for treatment with Emrelis.

Key results with the next-gen CEA ISAC are below: Bolt’s PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker.

The novel DNA topoisomerase I inhibitor T01 and the microtubule inhibitor MMAE, are conjugated to glycan on Fc via cleavable linkers, thereby achieving synergistic antitumor effects through the ...

They then constructed a PROTAR vaccine library by incorporating 22 distinct proteasome-targeting degrons (PTDs) into the C-terminus of the viral protein M1 via a conditionally cleavable linker ...

They then constructed a PROTAR vaccine library by incorporating 22 distinct proteasome-targeting degrons (PTDs) into the C-terminus of the viral protein M1 via a conditionally cleavable linker ...

It consists of a human IgG1 monoclonal antibody conjugated to a potent camptothecin-based TOP1i payload with a protease-cleavable linker, achieving an average DAR of 8. These promising preclinical ...

It consists of a human IgG1 monoclonal antibody conjugated to a potent camptothecin-based TOP1i payload with a protease-cleavable linker, achieving an average DAR of 8. In vitro, PF-08052666 ...

Biosynthesis and Bio Transformation Center, School of Life Sciences and Medicine, Shandong University of Technology (SDUT), Zibo, China Antimicrobial peptides (AMPs) are critical effectors of innate ...

Enhertu consists of a HER2 monoclonal antibody attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptide-based cleavable linkers. Enhertu (5.4 mg/kg) is ...

Department of Fibre and Polymer Technology, KTH Royal Institute of Technology, Teknikringen 58, 100 44 Stockholm, Sweden Department of Fibre and Polymer Technology, KTH Royal Institute of Technology, ...

Enzyme-Cleavable Methadone Prodrugs and Methods of Use Thereof¹ including both composition of matter and method of use claims. PF9001, the innovative medication covered by this patent ...